At a Glance
| Feature | Detail |
|---|---|
| Name / structure | AHK-Cu: L-alanyl-L-histidyl-L-lysine bound to copper(II); synthetic analogue of GHK-Cu |
| Origin | Cosmetic peptide research; first published hair data from Seoul National University (2007) |
| Mechanism | In the lab: stimulates dermal papilla cell proliferation, shifts Bcl-2/Bax toward survival, reduces cleaved caspase-3 and PARP |
| Used for | Hair thinning and androgenetic alopecia (cosmetic scalp products); skin care |
| Route | Topical serum or foam; some users inject subcutaneously |
| Typical dose range | Topical 0.05–1 % in products; injection 1–2 mg reported by users |
| Evidence level | Limited: one ex vivo/in vitro study on human follicles; no human trials |
| Regulatory status | Cosmetic ingredient; not an approved drug; not on FDA compounding lists; WADA 2026: injectable use of a non-approved substance falls under S0 |
AHK-Cu is what happens when a good idea gets marketed faster than it gets tested. Copper peptides have a real research history, almost all of it on GHK-Cu. AHK-Cu swaps one amino acid and has been positioned as the “hair” copper peptide on the strength of a single laboratory paper. Since then it has moved from scalp serums into vials sold for injection.
My verdict: the 2007 study is a reasonable starting point and nothing more. If you want to try a copper peptide on your scalp, a cosmetic serum is a low-risk experiment. Injecting AHK-Cu is an experiment with no human data at all.
How it works
Hair growth depends on the dermal papilla, a cluster of specialised fibroblasts at the base of the follicle that signals the follicle to grow (anagen) and to keep growing. Androgenetic alopecia shortens anagen and miniaturises follicles, partly through dermal papilla cell signalling and survival.
In the one study, AHK-Cu at extremely low concentrations (10⁻¹² to 10⁻⁹ M) did three things [1]:
- Lengthened human hair follicles kept alive in culture (ex vivo).
- Increased proliferation of cultured human dermal papilla cells.
- Raised the Bcl-2/Bax ratio and reduced cleaved caspase-3 and PARP, molecular signs of less apoptosis. The drop in the actual number of apoptotic cells did not reach statistical significance.
The authors cite earlier work showing that tripeptide-copper complexes stimulate dermal fibroblasts and VEGF production while lowering TGF-beta1 [1]. That fits with copper peptides acting as tissue-remodelling signals, as described in more depth for GHK-Cu [2].
What the evidence shows
| Study | Model | Concentration | Finding |
|---|---|---|---|
| Pyo 2007 [1] | Human hair follicles ex vivo; cultured human dermal papilla cells | 10⁻¹² – 10⁻⁹ M | Follicle elongation; more dermal papilla cell proliferation; anti-apoptotic protein shifts |
That is the published record. A PubMed search for AHK-Cu returns this one hair study; the other hits concern copper chemistry or unrelated peptides. There is no randomised trial, no uncontrolled clinical series and no published hair-count study in people. Whether a topical product delivers the peptide to the dermal papilla at a useful concentration is also untested; copper peptides are charged, water-soluble molecules that penetrate intact skin poorly without help such as microneedling.
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| Hair growth (laboratory) | 10⁻¹² – 10⁻⁹ M | Applied to follicles and cells in culture | Continuous | Days | Laboratory study [1] |
| Hair thinning, cosmetic | Products containing about 0.05–1 % AHK-Cu | Topical to scalp | Once or twice daily | 3–6 months before judging | Product convention (MyPeptideMatch dosage guide); Anecdotal |
| Hair thinning, injected | 1–2 mg (reported range 0.25 mg to far higher) | SC, near the scalp area | Daily or 3–5× weekly | 4–12 weeks | Anecdotal (Groundtruth report aggregator, r/tressless) |
| Common stacks | Topical AHK-Cu with minoxidil, finasteride, microneedling or GHK-Cu | Topical | Daily | Months | Anecdotal |
Notes:
- The laboratory effect occurred at picomolar to nanomolar concentrations. Cosmetic percentages are many orders of magnitude higher, and nobody knows how much reaches the follicle.
- Injected doses are borrowed from GHK-Cu conventions. No pharmacokinetic or safety study supports them.
- Microneedling is often combined with copper peptide serums to improve penetration. Microneedling has its own clinical evidence in hair loss, which makes any added effect of the peptide hard to judge.
For injection technique, see the peptide injection guide.
What people report: what works and what doesn’t
Reported to work
- Positive reports describe “baby hairs” after about 3 to 6 weeks of use. They come from a community aggregator of Reddit reports, which counted 22 experience reports: 15 positive, 2 mixed, 5 negative (Groundtruth). Self-selected reports skew positive and almost always involve other treatments at the same time.
- Some injecting users say their skin improved more than their hair.
Mixed or unclear
- Hair that “feels thicker” without visible regrowth after about 10 weeks of injections (r/tressless).
- Worries about effects on body hair with systemic use; there are no data either way.
Reported not to work, or disappointing
- Nothing after months of topical use, in about a quarter of the aggregated reports.
- Hard, dark blue-black lumps at injection sites lasting two weeks or more (r/FemaleHairLoss).
- “Copper uglies”, a community term for dullness or breakouts after starting copper peptides, discussed mainly for GHK-Cu; no study documents it.
What a proper trial would need to show: an increase in hair count and hair diameter on standardised phototrichograms after 6 months of a defined topical concentration, against vehicle, ideally with and without microneedling.
Safety and side effects
Topical copper peptides have a long cosmetic track record with low irritation; occasional redness, itching or contact allergy to copper are possible. AHK-Cu itself has no published safety study.
Injection raises different questions:
- No human safety or pharmacokinetic data.
- Local reactions: users describe painful, discoloured lumps.
- Copper load: small per dose, but systemic copper exposure from repeated injections has not been measured. People with Wilson’s disease or other disorders of copper metabolism should not use injected copper peptides.
- Grey-market vials: unknown content, purity and sterility.
Pregnancy and breastfeeding: no data. Hair loss that is new, patchy, sudden or accompanied by other symptoms needs a diagnosis (iron, thyroid, hormones, autoimmune alopecia) before any cosmetic peptide.
Legal and regulatory status
- United States. AHK-Cu is used as a cosmetic ingredient. It is not an approved drug and does not appear on FDA’s 503A bulks lists or on the significant-safety-risk list, which does include injectable GHK-Cu [3]. Selling it as an injectable for human use would make it an unapproved drug.
- EU and Germany. Permitted in cosmetics under the cosmetics regulation; a claim to treat hair loss would make a product a medicine. Injectable AHK-Cu for human use is not authorised.
- Sport. Not named on the WADA 2026 list. Injected as a non-approved substance, it falls under the S0 catch-all; topical cosmetic use is not targeted.
How it fits: AHK-Cu vs GHK-Cu and other hair options
| AHK-Cu | GHK-Cu | Minoxidil / finasteride | |
|---|---|---|---|
| Human hair data | None (lab only) | Limited | Randomised trials, approved |
| Skin and wound data | None | Controlled studies (topical) | Not applicable |
| Typical use | Topical serum, some injection | Topical, injection | Topical or oral |
For hair loss, approved treatments come first; copper peptides are add-ons with limited evidence. The site’s guide to peptides for hair loss compares GHK-Cu, TB-500 and KGF in more detail, and the GHK-Cu skin article covers the copper peptide with the most data.
Related Articles
- Peptides for Hair Loss: GHK-Cu, TB-500 and KGF
- GHK-Cu: The Copper Peptide for Tissue Remodeling
- GHK-Cu for Skin: Anti-Aging Evidence and Protocols
- SNAP-8: The Topical Anti-Wrinkle Peptide
- Peptide Injection Guide
Frequently asked questions
What is AHK-Cu?
AHK-Cu is a tripeptide (alanine-histidine-lysine) bound to copper. It differs from the better-known GHK-Cu by one amino acid and is marketed mainly for hair growth in scalp serums.
Does AHK-Cu work for hair loss?
The only published study tested it on isolated human hair follicles and dermal papilla cells in the laboratory, where it lengthened follicles and reduced markers of cell death. No clinical trial on people with hair loss has been published.
How is AHK-Cu used?
Most products are topical scalp serums containing roughly 0.05–1%. Some people inject 1–2 mg under the skin, a use with no published human data at all.
AHK-Cu vs GHK-Cu: which is better?
GHK-Cu has decades of skin and wound-healing research and some controlled human data for topical use. AHK-Cu has a single laboratory hair study. If you want the copper peptide with more evidence, GHK-Cu is it; for hair, both lack controlled trials.
References
- Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007. PMID: 17703734. https://pubmed.ncbi.nlm.nih.gov/17703734/
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015. PMID: 26236730. https://pubmed.ncbi.nlm.nih.gov/26236730/
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 22 April 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Disclaimer: This article is for information and education only and is not a prescription or individual medical advice. AHK-Cu is a cosmetic ingredient, not an approved treatment for hair loss.
